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CTRP2 Overexpression Improves Insulin and Lipid
Tolerance in Diet-Induced Obese Mice
Jonathan M. Peterson1,2.¤, Marcus M. Seldin1,2., Stefanie Y. Tan1,2, G. William Wong1,2*
1 Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 2 Center for Metabolism and Obesity
Research, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Abstract
CTRP2 is a secreted plasma protein of the C1q family that enhances glycogen deposition and fat oxidation in cultured
myotubes. Its in vivo metabolic function, however, has not been established. We show here that acute and chronic
metabolic perturbations induced by fasting or high-fat feeding up-regulated the mRNA expression of Ctrp2 in white adipose
tissue without affecting its circulating plasma levels. We generated a transgenic mouse model with elevated circulating
levels of CTRP2 to determine its metabolic function in vivo. When fed a low-fat diet, wild-type and CTRP2 transgenic mice
exhibited no metabolic phenotypes. When challenged with a high-fat diet to induce obesity, wild-type and CTRP2
transgenic mice had similar weight gain, adiposity, food intake, metabolic rate, and energy expenditure. Fasting serum lipid
and adipokine profiles were also similar between the two groups of mice. However, while glucose and insulin levels in the
fasted state were comparable between wild-type and CTRP2 transgenic mice, insulin levels in the fed state were consistently
lower in transgenic mice. Notably, CTRP2 transgenic mice had improved insulin tolerance and a greater capacity to handle
acute lipid challenge relative to littermate controls. Our results highlight, for the first time, the in vivo role of CTRP2 in
modulating whole-body metabolism.
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and the truncated globular form of CTRP2 enhance fatty acid
oxidation, as well as glycogen deposition, in differentiated mouse
C2C12 myotubes [1]. Our previous in vitro study suggests a role for
CTRP2 in regulating carbohydrate and lipid metabolism; its in vivo
metabolic function, however, has not been established. In contrast,
several related CTRPs have recently been shown to play
important roles in controlling glucose and/or lipid metabolism
in mice [4,7,10,11,12,13]. In the current study, we used a
transgenic mouse model to examine the in vivo metabolic function
of CTRP2 in regulating energy balance.

Introduction
C1q/TNF-related proteins (CTRPs) are secreted proteins with
notable metabolic functions [1,2,3,4,5,6,7,8]. CTRPs, and the
insulin-sensitizing adipokine adiponectin, belong to the C1q
family, resemble each other in overall domain structure and
organization, and share sequence homology with the globular
domain of immune complement C1q [9]. Each CTRP has a
unique tissue expression profile and most circulate in plasma as
multimeric glycoproteins [9]. Functional studies of CTRPs in mice
suggest non-redundant metabolic, vasculoprotective, and cardioprotective functions for this class of secreted hormones
[4,7,10,11,12,13,14,15,16,17,18,19].
We identified CTRP2 as a secreted protein homologous to
adiponectin [1]. CTRP2 shares 42% amino acid identity with
adiponectin at the presumed functional globular C1q domain [1]
and is expressed predominantly in adipose tissue. It also circulates
as a trimeric glycoprotein in plasma [3]. Expression of Ctrp2
transcript is up-regulated in young (8-week-old) but not older (12week-old) leptin-deficient ob/ob mice; this is thought to be a
compensatory response to leptin deficiency prior to the development of morbid obesity and severe insulin resistance [3].
Recombinant CTRP2 activates the conserved energy sensor
AMP-activated protein kinase (AMPK) in a dose-dependent
manner, similar to adiponectin [1]. Both the full-length protein
PLOS ONE | www.plosone.org

Materials and Methods
Antibodies and Chemicals
Rat monoclonal anti-HA antibody (clone 3F10) was obtained
from Roche Applied Science. Rabbit polyclonal anti-CTRP2
antibody was obtained from ProSci Inc. (Poway, CA; catalog no.
3561). Beta-tubulin HRP-conjugated antibody was obtained from
Abcam (Cambridge, MA; catalog no. ab21058). Rabbit polyclonal
antibodies recognizing phospho-AMPK (Thr-172), AMPK, phospho-ACC (Ser-79), and ACC were obtained from Cell Signaling
Technology (Danvers, MA).
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Figure 1. Diet and metabolic state modulate the expression of CTRP2. A, Quantitative real-time PCR analyses of Ctrp2 expression in brown
adipose tissue (BAT), visceral (epididymal fat pad), and subcutaneous (SubQ; inguinal fat pad) white adipose tissue from ad libitum fed (n = 10) or
overnight (16 h) fasted male mice (n = 10). B, Quantitative Western blot analysis of CTRP2 serums levels in ad libitum fed or overnight (16 h) fasted
male mice. Each lane represents data from an independent mouse. C-D, Real-time PCR (C) and Western blot (D) analysis of CTRP2 mRNA and serum
levels in male C57BL/6 mice fed a high-fat diet (HFD) or a low-fat diet (LFD) for 12 weeks. Each lane on the immunoblot represents data from an
independent mouse. Values shown are mean 6 SEM. (n = 8–10 mice per group) *p,0.05.
doi:10.1371/journal.pone.0088535.g001

Animal Care and Use Committee of The Johns Hopkins
University School of Medicine (protocol number MO11M49).

Animals
C57BL/6J male mice (The Jackson Laboratory, Bar Harbor,
ME) were used to evaluate diet-induced changes in Ctrp2 mRNA
and circulating levels. Sera were obtained from wild-type male
mice following ad libitum feeding or overnight (16 h) fast; for the ad
libitum fed group, serum samples were obtained at 2–3 h into the
light cycle. Circulating CTRP2 levels were quantified by Western
blot. CTRP2 transgenic (Tg) mice and wild-type (WT) control
littermates were housed in polycarbonate cages on a 12-h lightdark photocycle with ad libitum access to water throughout the
study period. Mice were fed ad libitum a high-fat diet (HFD; 60%
kcal derived from fat, Research Diets, New Brunswick, NJ;
D12492) or a matched, control low-fat diet (LFD; 10% kcal
derived from fat, Research Diets; D12450B), beginning at 4 weeks
of age. HFD was provided for a period of 12 weeks. Blood samples
were collected after 12 weeks for serum analysis. For terminal
experiments, mice were sacrificed by decapitation under anesthesia. All studies accorded with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. All animal experiments were approved by the

PLOS ONE | www.plosone.org

Generation of CTRP2 Transgenic (Tg) Mice
C-terminal HA-epitope tagged CTRP2 was cloned into the XhoI
site of the pCAGGS vector (25). Expression of CTRP2 transgene
was driven by the ubiquitious CAG promoter, which consists of a
CMV enhancer element with a chicken b-Actin promoter. The
plasmid construct was digested with SalI and NotI restriction
enzymes (New England Biolabs, Ipswich, MA) and resulting DNA
fragments (,3.3 and 2.5 kb) were separated on a 1% agarose gel.
The ,3.3-kb linear DNA fragment containing the CAG promoter
and enhancer, CTRP2-HA transgene, and the rabbit b-globin
polyA adenylation signal was excised from the agarose gel,
purified, and verified by DNA sequencing. Pronuclear injections
were performed; several transgenic founder lines were obtained,
and one line was expanded for phenotypic analysis. The transgenic
line was generated on a C57BL/6J genetic background. No
backcross was necessary. Transgene-negative male littermates
were used as WT control mice for transgene-positive male mice
throughout the study.
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Figure 2. Generation of CTRP2 transgenic mice. A, Schematic of Ctrp2 transgene construct. HA epitope-tagged Ctrp2 transgene is driven by the
ubiquitous CAG promoter. B, RT-PCR analysis demonstrating the presence of Ctrp2 transgene in Tg mice. C, Western blot analysis of CTRP2 in sera
from WT and Tg mice. D, Quantification of relative band intensity (arbitrary unit) as shown in C. E, Western blot analysis of CTRP2-HA protein in mouse
tissues.
doi:10.1371/journal.pone.0088535.g002

metabolic phenotyping core facility at the Johns Hopkins
University School of Medicine. EchoMRI analysis provided values
for fat mass, lean mass, and water content.

RT-PCR Analysis
Total RNAs from mouse tissues were isolated with TRIzolH
(Invitrogen). One mg of total RNA were reverse-transcribed using
Superscript II (Invitrogen). Thirty-cycle PCR was carried out
using Hot Start Taq Blue polymerase (Denville); the cycling
conditions were as follows: 15 s denaturation at 95uC, 15 s primer
annealing at 60uC, and 45 s primer extension at 72uC. Primers
used included the following: forward (4F7) 59- CTGCGGCAGTAGCCGAGC CAAGTCG-39 and reverse (HA-Tag-R) 59TCAAGCGTAGTCTGGGACGTCGTATGGGTA-39.

Indirect Calorimetry
CTRP2 Tg mice and WT control littermates were used for
simultaneous assessments of daily changes in body weight, energy
intake (corrected for spillage), and whole-body metabolic profile in
an open-flow indirect calorimeter (Oxymax, Columbus Instruments) as described previously [12]. Data were collected for three
days to confirm acclimation to the calorimetry chambers (stable
body weights and food intakes), and data from the fourth day were
analyzed. Rates of oxygen consumption (VO2, mL/kg/h) and
carbon dioxide production (VCO2) were measured for each
chamber every 16 min throughout the studies. Respiratory
exchange ratio (RER = VCO2/VO2) was calculated using Oxymax software (v. 4.02) to estimate relative oxidation of carbohydrate (RER = 1.0) versus fat (RER approaching 0.7), not
accounting for protein oxidation. Energy expenditure was
calculated as EE = VO2 x [3.815+(1.2326RER)] [20], and
normalized to body mass (kcal/kg/h).

Mouse Serum and Blood Chemistry Analysis
Mouse serum samples were harvested by tail bleeding after
overnight fast (,16 h), or at the indicated time point. Serum
samples were separated using microvetteH CB 300 (Sarstedt).
Glucose concentration was determined at the time of collection
with a glucometer (BD bioscience). Serum triglycerides, nonesterified free fatty acids (NEFA), cholesterol, high-density
lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL)
cholesterol were measured at the Phenotyping Core at the Johns
Hopkins University School of Medicine. Serum insulin, leptin,
resistin, adiponectin, PAI-1, and TNF-a (Millipore) were measured according to kit manufacturer’s instructions.

Intraperitoneal Glucose, Insulin, Pyruvate, and Lipid
Tolerance Tests

Body Composition Analysis

During glucose tolerance tests (GTT), animals were fasted
overnight (,16 h), and glucose (1 g/kg) was injected intraperitoneally (IP). During insulin tolerance tests (ITT), food was removed

Body compositions of WT and Tg mice were determined using
a whole-body NMR instrument (EchoMRI, Waco, TX) at the
PLOS ONE | www.plosone.org
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Figure 3. Body weight and body composition analysis of CTRP2 transgenic mice. A, Body weight gain over time between WT (n = 9) and Tg
(n = 11) male mice fed a low-fat diet (LFD). B, Body weight gain over time between WT (n = 18) and Tg (n = 24) male mice fed high-fat diet (HFD). C,
Total, fat, and lean mass in WT (n = 8) and Tg (n = 7) male mice as determined by NMR analysis. D, Weight of epipidymal fat pad, heart, and liver of WT
(n = 11) and Tg (n = 9) male mice fed an LFD, as well as WT (n = 8) and Tg (n = 10) mice fed an HFD. Values shown are mean 6 SEM.
doi:10.1371/journal.pone.0088535.g003

Figure 4. Indirect calorimetry analysis of CTRP2 transgenic mice fed a high-fat diet. A, Food intake analysis in WT (n = 7) and Tg (n = 8)
mice on a high-fat diet. B-D, Oxygen consumption (VO2; B), respiratory exchange ratio (RER = VCO2/VO2; C), and energy expenditure (D) of WT (n = 7)
and Tg (n = 8) male mice on a high-fat diet as determined by indirect calorimetry. Values shown are mean 6 SEM.
doi:10.1371/journal.pone.0088535.g004

PLOS ONE | www.plosone.org
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Figure 5. Insulin sensitivity in CTRP2 transgenic mice. A–B, Fasting glucose (A) and insulin (B) levels in WT (n = 8) and Tg (n = 11) mice. C, Serum
insulin levels in the fed state in WT (n = 13) and Tg (n = 8) mice. D-E, Glucose (D) and insulin (E) tolerance test in WT (n = 9) and Tg (n = 10) mice. F,
Pyruvate tolerance test in WT (n = 10) and Tg (n = 8) mice. Values shown are mean 6 SEM. *p,0.05 vs. WT.
doi:10.1371/journal.pone.0088535.g005

NEFA and triglycerides were quantified using kits from Wako and
Infinity Triglycerides, respectively.

2 h prior to insulin (1.2 U/kg) injection. During pyruvate
tolerance tests (PTT), mice were fasted overnight (,16 h) and
then IP-injected with 2 g/kg body weight sodium pyruvate
(Sigma-Aldrich) in saline. Blood glucose levels during GTT,
ITT, and PTT were measured using a glucometer (BD
Pharmingen) at the indicated time points. During lipid tolerance
tests (LTT), mice were fasted 12 h and then IP injected with 20%
emulsified Intralipid (soybean oil; Sigma; 10 mL/g of body weight).
Sera were collected via tail bleed using a MicrovetteH CB 300
(Sarstedt) at 0, 1, 2, 3, and 5 h post-injection. Serum levels of

PLOS ONE | www.plosone.org

b3-adrenergic Receptor Agonist Stimulation
Mice were fasted for 2 h, then injected with 1 g/kg body weight
of CL316,243 hydrate (b3 adrenergic receptor agonist, Sigma).
Blood glucose and sera were harvested via tail bleed at 0, 15, 30,
60, and 120 min post-injection. Serum NEFA levels were
measured with a NEFA kit (Wako).

5

February 2014 | Volume 9 | Issue 2 | e88535

Metabolic Function of CTRP2 In Vivo

Figure 6. Lipid tolerance in CTRP2 transgenic mice. A–B, Serum non-esterified free fatty acid (NEFA) levels in WT (n = 9) and Tg (n = 6) mice over
time in response to emulsified lipid infusion. C–D, Serum triglyceride (TG) levels in WT (n = 9) and Tg (n = 6) mice over time in response to emulsified
lipid infusion. E-F, Blood glucose and serum NEFA over time in WT (n = 8) and Tg (n = 11) in response to b3 adrenergic receptor agonist
administration. Values shown are mean 6 SEM. *p,0.05 vs. WT. **p,0.01.
doi:10.1371/journal.pone.0088535.g006

Samples were electrophoresed on 10% BisTris NuPAGE gels
(Invitrogen, Carlsbad, CA), transferred to 0.2 mm Protran BA83
nitrocellulose membranes (GE Healthcare, Piscataway, NJ), and
probed with the CTRP2 primary antibody and appropriate HRPconjugated secondary antibody. Bands were visualized with
Immobilon Western HRP substrate peroxide solution (Millipore,
Billerica, MA), captured with MultiImage III FluorChemH Q
(Alpha Innotech, San Leandro, CA), and quantified using
Alphaview Software (Alpha Innotech).

Isolation of Skeletal Muscle, Liver, and Adipose Tissue
Liver, adipose tissue, and skeletal muscle samples were
immediately harvested from euthanized mice and snap-frozen in
liquid nitrogen. Homogenized cell lysates were prepared in lysis
buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5%
NP-40, and 10% glycerol) containing protease and phosphatase
inhibitor cocktails (Sigma-Aldrich). Protein content was quantified
using Coomasie Plus protein reagent (Thermo Scientific).

Immunoblot Analysis

Statistical Analysis

Western blot analysis was carried out as previously described
[12]. For tissue lysates, 40 mg from each sample was loaded. For
serum samples, one mL-equivalent serum samples were suspended
in NuPAGE LDS sample buffer and heated for 5 min at 90uC.
PLOS ONE | www.plosone.org

All results are expressed as mean 6 standard error of the mean
(SEM). Statistical analysis was performed with Prism 5 software
(GraphPad). Blood chemistry data were analyzed with two-tailed
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Weight Gain, Food Intake, and Energy Expenditure of
CTRP2 Tg Mice Fed a Low- or High-fat Diet

Table 1. Serum lipid and adipokine profiles between WT and
CTRP2 Tg mice.

WT

Tg

NEFA (mEq/L)

0.8260.08

0.7660.06

Triglycerides (mg/dL)

58.663.9

59.163.1

Total cholesterol (mg/dL)

99.168.4

106.469.9

HDL-cholesterol (mg/dL)

44.663.1

51.264.7

LDL-cholesterol (mg/dL)

42.866.2

43.465.5

Leptin (ng/mL)

7.261.6

6.361.3

Adiponectin (mg/mL)

14.661.0

12.561.7

Resistin (ng/mL)

1.460.15

1.3760.10

TNF-a (pg/mL)

6.060.2

6.260.2

PAI-1 (ng/mL)

2.7860.6

2.6960.5

CTRP2 Tg mice were born in the expected Mendelian ratio
and developed normally with no gross phenotypic abnormality.
Body weight gain on LFD (Fig. 3A) and HFD (Fig. 3B) over a
period of 8 weeks was indistinguishable between Tg and WT male
mice. We obtained similar body weight data on multiple
independent cohorts of WT and Tg mice (data not shown). For
this reason, we chose to focus our analysis on HFD-fed male mice
throughout the study. Consistent with the body weight data, we
observed no differences in fat and lean mass between WT and
CTRP2 Tg mice (Fig. 3C), nor any differences in heart, liver, and
epididymal fat pad weight between the two groups of animals
(Fig. 3D). Indirect calorimetry analysis also revealed no differences
in food intake, oxygen consumption (a measure of metabolic rate),
respiratory exchange ratio (a measure of fat vs. carbohydrate
oxidation), or energy expenditure between WT and CTRP2 Tg
mice (Fig. 4).

Quantification of fasting serum lipid metabolites and adipokines levels in WT
(n = 10) and Tg (n = 10) male mice.
doi:10.1371/journal.pone.0088535.t001

Improved Insulin Tolerance in Obese CTRP2 Tg Mice
We observed no differences in fasting glucose and insulin levels
between WT and CTRP2 Tg mice (Fig. 5A,B). However, we
consistently noted that CTRP2 Tg mice had lower blood glucose
in the fed state (Fig. 5C). This was confirmed in separate cohorts of
WT and Tg mice, suggesting that the Tg animals may be more
insulin-sensitive in the fed state. We performed glucose tolerance
tests in overnight-fasted mice and observed no difference in the
rate of glucose disposal in the peripheral tissues between WT and
CTRP2 Tg animals (Fig. 5D). In contrast, during insulin tolerance
tests the rate of glucose disposal in the peripheral tissues was
greater in CTRP2 Tg mice relative to WT littermate controls
(Fig. 5E), consistent with improved insulin action. Improved
insulin tolerance was seen only in the HFD-fed Tg mice and not
the LFD-fed Tg mice (data not shown). To assess possible changes
in hepatic insulin sensitivity, we performed a pyruvate tolerance
test. In overnight-fasted mice where hepatic glycogen has been
depleted, pyruvate (a gluconeogenic substrate) will be converted to
glucose in the liver to buffer blood glucose [21]. Because insulin
suppresses hepatic gluconeogenesis, the rate of hepatic glucose
output in response to pyruvate administration indicates the extent
of insulin sensitivity in the liver. Here, when overnight-fasted mice
were given sodium pyruvate, no differences in hepatic glucose
production were observed between WT and CTRP2 Tg mice
(Fig. 5F).

Student’s t-tests between CTRP2 Tg and WT control littermates.
Average metabolic values (from indirect calorimetry) were
calculated within subjects, then averaged across subjects for
statistical analysis by Student’s t-test. Repeated measures ANOVA
were performed on body weights as well as serum glucose,
triglyceride, and NEFA measurements in various tolerance tests.
Values were considered to be significant at p,0.05.

Results
Alteration in CTRP2 mRNA and Circulating Levels in
Response to Metabolic Perturbation
Expression and/or circulating levels of multiple CTRPs change
in response to alterations in energy state [5,6,7,10,12,13]. We
therefore determined whether the expression and plasma levels of
CTRP2 change in response to acute and chronic metabolic
perturbation. Wild-type C57BL/6 male mice fasted overnight
(,16 h) had ,4-fold higher transcript levels of Ctrp2 in the
subcutaneous white adipose tissue (subcutaneous fat pad) and 25%
higher circulating CTRP2 levels compared to ad libitum-fed
animals (Fig. 1A,B). In diet-induced obese male mice fed a HFD
for 12 weeks, we observed an approximately 2-fold increase in the
expression of Ctrp2 transcript in the visceral white adipose tissue
(epididymal fat pad) (Fig. 1C). However, no significant changes
were detected in the circulating levels of CTRP2 in HFD-fed mice
(Fig. 1D). These results indicate that short-term changes in
nutritional state, as well as chronic metabolic perturbation induced
by HFD, had an impact on the expression of Ctrp2.

Improved Lipid Tolerance in Obese CTRP2 Tg Mice
To determine whether the HFD-fed WT and Tg mice differ in
their capacity to handle acute lipid challenge we performed a lipid
tolerance test. Fasted mice were IP-injected with emulsified lipids,
mimicking the sudden rise of plasma lipids in response to food
intake [22], and the circulating levels of NEFA and triglycerides
were quantified over time. The CTRP2 Tg mice demonstrated a
significantly greater capacity to clear an acute rise in free fatty
acids and triglycerides in response to emulsified lipid infusion
compared to WT controls (Fig. 6A–D), suggesting an enhanced
capacity to handle lipid load. Improvements in lipid tolerance
were only seen in the HFD-fed and not in the LFD-fed Tg mice
(data not shown). Next, we determined whether CTRP2 Tg mice
had an altered capacity to mobilize free fatty acids from adipose
tissue in response to fasting or sympathetic input (via the b3adrenergic receptor). Overnight fast did not lead to any differences
in serum non-esterified free fatty acids (NEFA) (Table 1).
Administration of a b3-adrenergic receptor agonist (CL316,243)

Generation of CTRP2 Transgenic Mice
To identify the in vivo metabolic function of CTRP2, we
generated a Tg mouse model over-expressing HA epitope-tagged
CTRP2. Because CTRP2 is a secreted protein and is normally
expressed in multiple tissues and cell types in mice [1,3], we chose
to express the Ctrp2 transgene using a ubiquitous promoter
(Fig. 2A,B). The Tg mouse line had a modest 2-fold higher
circulating level of CTRP2 relative to wild-type littermate controls
(Fig. 2C,D). At the protein level, we detected the HA-tagged
CTRP2 in the skeletal muscle, heart, adipose tissue, liver, spleen,
testis, and brain of transgenic animals (Fig. 2E).

PLOS ONE | www.plosone.org
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to WT and Tg animals also revealed no differences in agonistinduced rise in blood glucose (Fig. 6E) or the release of free fatty
acids from adipose tissue triglycerides (Fig. 6F).

physiologic compensations that could mask the true impact of
CTRP2 on systemic glucose and lipid metabolism. Alternatively,
there may be a threshold effect for CTRP2; the presence of more
CTRP2 protein due to transgenic overexpression would not lead
to further improvements in metabolic profile of these animals.
Employing a CTRP2 loss-of-function mouse model in future
studies will help clarify and establish its physiologic role in
modulating energy metabolism.
In contrast to the modest phenotypes seen in CTRP2 Tg mice,
overexpressing the related CTRP family members–CTRP1,
CTRP3, and CTRP9–in mice using a similar transgenic approach
has resulted in significant improvements in the metabolic profiles
of these animals compared to WT littermate controls [10,11,12].
When fed an HFD, CTRP1 Tg mice have lower body weights due
to increased energy expenditure, leading to greater systemic
insulin sensitivity [10]. CTRP1 Tg mice also have higher basal
AMPK activation in the skeletal muscle, leading to enhanced fat
oxidation [10]. While no differences in body weight, energy
expenditure, and glucose tolerance are observed between CTRP3
Tg and WT mice, the transgenic animals are strikingly resistant to
the development of fatty liver (steatosis) in response to high-fat
feeding [11]. Overexpressing CTRP3 in mice suppresses the
expression of genes (Gpat, Agpat, Dgat) involved in triglyceride
synthesis, leading to decreased triglyceride accumulation in the
liver of the Tg animals [11]. Of the CTRP Tg mouse models
described to date, the most dramatic and striking phenotypes are
observed in mice overexpressing CTRP9 [12]. CTRP9 Tg mice
are lean and resistant to weight gain when fed an HFD. All the
metabolic dysfunctions (insulin resistance, obesity, fatty liver,
dyslipidemia) associated with high-fat feeding are prevented in
CTRP9 Tg mice [12]. These remarkable metabolic phenotypes
are due to a combination of reduced caloric intake and increased
energy metabolism [12]. The present study and recent findings
using transgenic mouse models suggest that each CTRP has a
unique role in regulating glucose and/or lipid metabolism in vivo,
consistent with their high degree of conservation throughout
vertebrate evolution [9].

Serum Lipid and Adipokine Profiles of Obese CTRP2 Tg
Mice
Circulating levels of lipid metabolites and adipokines are tightly
linked to metabolic state. We performed blood chemistry analysis
on the HFD-fed WT and CTRP2 Tg mice and observed no
differences in serum lipid (NEFA, triglycerides, total cholesterol,
HDL-cholesterol, and LDL-cholesterol) or adipokine (leptin,
adiponectin, resistin, TNF-a, and PAI-1) levels between the two
groups of animals (Table 1). Similarly, we observed no differences
in serum metabolite and adipokine profiles in the LFD-fed WT
and Tg mice (data not shown).

Discussion
Using a transgenic mouse model, we sought to determine a role
for CTRP2 in regulating whole-body metabolism in vivo. Whether
in the context of an LFD or the metabolic challenge of an HFD,
CTRP2 over-expression in Tg mice had little impact on the
multiple metabolic parameters examined. These included food
intake, body weight, energy expenditure, and serum lipid and
adipokine profiles. However, insulin tolerance tests suggested that
CTRP2 Tg mice do exhibit improved insulin action, indicated by
an increased rate of glucose disposal in the peripheral tissues in
response to insulin administration. The improvements in insulin
tolerance relative to WT littermate controls were only seen in the
CTRP2 Tg mice fed an HFD and not if they were fed the control
LFD. Similarly, the HFD-fed CTRP2 Tg mice showed an
enhancement in the capacity of Tg animals to handle an acute
lipid challenge, as indicated by a greater rate of free fatty acids and
triglyceride clearance in response to emulsified lipid infusion.
Despite improvements in acute lipid tolerance, CTRP2 Tg mice
chronically fed an HFD did not show any differences in body
weight or fat mass compared to WT littermate controls. Our
previous in vitro studies suggest that recombinant CTRP2 activates
AMPK signaling to enhance fat oxidation in mouse C2C12
myotubes [1]. Overexpressing CTRP2 in mice, however, did not
result in higher basal AMPK activation. We did not observe any
differences in the phosphorylation and activation of AMPKa, nor
its downstream target, acetyl-CoA carboxylase (ACC) in the
skeletal muscle, liver, or adipose tissue of WT and Tg animals (Fig.
S1). Nor did we observe any differences in fat oxidation in CTRP2
Tg mice, as indicated by the VO2 and respiratory exchange ratio
(RER). While in vitro studies using cultured cells and purified
recombinant protein are informative, our Tg mouse study
highlights the complexity of the in vivo milieu, where cells receive
multiple positive and negative inputs concurrently, a physiological
context that is difficult to capture in vitro. Interestingly, we did
observe a 2-fold higher basal level of p44/42-MAPK activation, as
judged by Thr-202/Tyr-204 phosphorylation, in the liver of
CTRP2 Tg mice relative to WT controls (data not shown); the
significance of this observation is unclear since the pyruvate
tolerance test we performed to evaluate hepatic insulin sensitivity
was not different between WT and Tg mice. Given that energy
balance is governed by multiple homeostatic mechanisms, the
caveats of over-expressing CTRP2 in mice include potential

Supporting Information
Figure S1 Basal AMPKa (Thr-172) and ACC (ser-79) phosphorylations in the skeletal muscle, liver, and adipose tissue of WT
and CTRP2 Tg mice fed a high-fat diet (n = 3 per group). Each
lane represents tissue sample from a different mouse. Replicate
blots were probed for phospho and total AMPK and ACC. PACC, phospho Acetyl-CoA carboxylase; p-AMPK, phospho
AMP-activated protein kinase.
(TIF)
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